AR117423A1 - METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A CONJUGATE OF ANTI-TISSUE ANTI-FACTOR ANTIBODY AND A DRUG - Google Patents

METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A CONJUGATE OF ANTI-TISSUE ANTI-FACTOR ANTIBODY AND A DRUG

Info

Publication number
AR117423A1
AR117423A1 ARP190101201A ARP190101201A AR117423A1 AR 117423 A1 AR117423 A1 AR 117423A1 AR P190101201 A ARP190101201 A AR P190101201A AR P190101201 A ARP190101201 A AR P190101201A AR 117423 A1 AR117423 A1 AR 117423A1
Authority
AR
Argentina
Prior art keywords
antibody
cdrs
methods
combination
conjugate
Prior art date
Application number
ARP190101201A
Other languages
Spanish (es)
Original Assignee
Genmab As
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As, Merck Sharp & Dohme filed Critical Genmab As
Publication of AR117423A1 publication Critical patent/AR117423A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona un anticuerpo anti-PD-1 que comprende las regiones de determinantes de complementariedad (CDRs) de pembrolizumab en combinación con un conjugado anticuerpo-droga que se une a factor de tejido (TF) que comprende monometil auristatina E y las CDRs de tisotumab (por ej., tisotumab vedotin) y su uso en métodos para tratar cáncer, tal como cáncer de mama y cáncer cervical. La presente también proporciona composiciones y kits que comprende el anticuerpo anti-PD-1 que comprende las CDRs de pembrolizumab y el conjugado anticuerpo-droga que se une a TF que comprende monometil auristatina E y las CDRs de tisotumab (por ej., tisotumab vedotin) para usar para trata cáncer, tal como cáncer de mama y cáncer cervical.The present provides an anti-PD-1 antibody comprising the complementarity determinant regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (eg, tisotumab vedotin) and its use in methods of treating cancer, such as breast cancer and cervical cancer. The present also provides compositions and kits comprising the anti-PD-1 antibody comprising the pembrolizumab CDRs and the TF-binding antibody-drug conjugate comprising monomethyl auristatin E and the tisotumab CDRs (eg, tisotumab vedotin ) for use to treat cancer, such as breast cancer and cervical cancer.

ARP190101201A 2018-05-07 2019-05-07 METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A CONJUGATE OF ANTI-TISSUE ANTI-FACTOR ANTIBODY AND A DRUG AR117423A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862668088P 2018-05-07 2018-05-07

Publications (1)

Publication Number Publication Date
AR117423A1 true AR117423A1 (en) 2021-08-04

Family

ID=77568166

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101201A AR117423A1 (en) 2018-05-07 2019-05-07 METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A CONJUGATE OF ANTI-TISSUE ANTI-FACTOR ANTIBODY AND A DRUG

Country Status (1)

Country Link
AR (1) AR117423A1 (en)

Similar Documents

Publication Publication Date Title
CO2021016552A2 (en) mcl-1 inhibitory antibody-drug conjugates and their methods of use
EA202092136A1 (en) METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG
MX2020011823A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate.
BR112015027474A8 (en) antibody, composition, method of treatment of the cancer patient and use of an antibody.
ZA201907225B (en) Treatment of her2 positive cancers
BR112021015036A2 (en) Cancer treatment with ror1 antibody immunoconjugates
CO2022002573A2 (en) Antibodies against ilt2 and their use
BR112022008756A2 (en) ANTI-MESOTHELIN ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MX2021010116A (en) Anti-pd-l1 antibody and use thereof.
AR120147A1 (en) ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
MX2020004265A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
ECSP21044421A (en) ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
CR20230128A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
CO2024013569A2 (en) Binding molecules against frα
CO2021016982A2 (en) Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of bile duct cancers
EA202190734A1 (en) METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY AGAINST VEGF AND ANTIBODY ANTIBODY AGAINST TISSUE FACTOR-DRUG
BR112022009482A2 (en) MONOCLONAL ANTI-B7-H3 ANTIBODY AND METHODS OF USE THEREOF
AR117423A1 (en) METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A CONJUGATE OF ANTI-TISSUE ANTI-FACTOR ANTIBODY AND A DRUG
BR112017028012A2 (en) THERAPY COMBINED WITH AN ANTIBODY-ANTI-HER2 DRUG CONJUGATE AND A BCL-2 INHIBITOR
MX2022015375A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
MX2022004988A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate.
BR112022011268A2 (en) COMBINATION THERAPY WITH LIV1-ADC AND PD1 ANTAGONIST
BR112022008661A2 (en) METHOD TO TREAT CANCER IN A SUBJECT, ANTIBODY DRUG CONJUGATE THAT BINDS TO TISSUE FACTOR, USE OF AN ANTIBODY DRUG CONJUGATE, AND KIT
EA202092666A1 (en) METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG
EA202091951A1 (en) METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY BASED ON PLATINUM AND ANTIBODY CONJUGATE TO TISSUE FACTOR WITH A DRUG